We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+20.93%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$952M
AUM Growth
+$119M
(+14%)
Cap. Flow
+$35M
Cap. Flow
% of AUM
3.68%
Top 10 Holdings %
Top 10 Hldgs %
45.23%
Holding
168
New
60
Increased
16
Reduced
31
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heron Therapeutics
HRTX
|
+$23.5M |
| 2 |
PTC Therapeutics
PTCT
|
+$18.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$16.8M |
| 4 |
Travere Therapeutics
TVTX
|
+$16.1M |
| 5 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$15.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$48M |
| 2 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$31.8M |
| 3 |
MannKind Corp
MNKD
|
+$19.8M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$18.2M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.66% |
| 2 | Technology | 0.04% |
| 3 | Industrials | 0.02% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Talphera
TLPH
$67.5M
| $79M | 8.3% |
328,703
| – | – |
|
2
Neurocrine Biosciences
NBIX
$18.3B
| $74.4M | 7.81% |
4,619,367
+435,630
| +10% | +$7.45M |
|
|
3
Sarepta Therapeutics
SRPT
$1.62B
| $69.2M | 7.27% |
2,878,979
-605,600
| -17% | -$15.4M |
|
|
4
Vertex Pharmaceuticals
VRTX
$124B
| $41.1M | 4.32% |
581,728
-230,000
| -28% | -$18.2M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $36.3M | 3.81% |
1,230,070
-216,500
| -15% | -$6.82M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $28.8M | 3.02% |
412,400
-606,000
| -60% | -$48M |
|
|
EXAS
7
DELISTED
Exact Sciences
EXAS
| $25.9M | 2.72% |
1,825,150
-144,753
| -7% | -$1.95M |
|
|
8
Heron Therapeutics
HRTX
$93.6M
| $24.5M | 2.58% |
+1,762,426
| New | +$23.5M |
|
|
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
| $23M | 2.42% |
2,562,674
+230,000
| +10% | +$2.09M |
|
|
10
Travere Therapeutics
TVTX
$5.14B
| $22.1M | 2.33% |
+1,044,292
| New | +$16.1M |
|
|
11
PUT
Vertex Pharmaceuticals
VRTX
$124B
| $21.2M | 2.23% |
+300,000
| New | +$23.8M |
|
|
WBA
12
DELISTED
Walgreens Boots Alliance
WBA
| $20.1M | 2.11% |
304,419
-17,581
| -5% | -$1.1M |
|
|
COV
13
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $19.4M | 2.03% |
262,900
-111,926
| -30% | -$7.81M |
|
|
14
PTC Therapeutics
PTCT
$6.21B
| $17.6M | 1.84% |
+671,736
| New | +$18.1M |
|
15
Xencor
XNCR
$1.44B
| $17.5M | 1.83% |
1,488,672
-80,000
| -5% | -$840K |
|
|
NEPT
16
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $16.6M | 1.74% |
4,786
+571
| +14% | +$2.33M |
|
|
17
Acadia Pharmaceuticals
ACAD
$4.47B
| $16.2M | 1.7% |
+666,000
| New | +$16.8M |
|
|
ARAV
18
DELISTED
Aravive, Inc. Common Stock
ARAV
| $15.1M | 1.58% |
+83,544
| New | +$15.3M |
|
|
SGMO
19
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $14.5M | 1.52% |
+800,000
| New | +$15.4M |
|
20
Prothena Corp
PRTA
$443M
| $13.4M | 1.41% |
+350,000
| New | +$11.3M |
|
|
ANAC
21
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $12.9M | 1.36% |
647,015
+159,473
| +33% | +$3.09M |
|
|
EXAS
22
PUT
DELISTED
Exact Sciences
EXAS
| $12.8M | 1.34% |
+900,000
| New | +$12.2M |
|
23
MacroGenics
MGNX
$234M
| $12.5M | 1.31% |
448,945
-268,760
| -37% | -$9.49M |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| $11.9M | 1.25% |
172,217
+141,632
| +463% | +$10.4M |
|
|
ZLTQ
25
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $11.5M | 1.21% |
586,013
+280,420
| +92% | +$5.47M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q1 2014 Portfolio in Review
As of Q1 2014, Perceptive Advisors held 168 positions worth $952M, up 14% from $833M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Perceptive Advisors deployed $35M of net new capital in Q1 2014, opening 60 new positions and adding to 16 existing holdings. Its largest new stake was Heron Therapeutics: 1,762,426 shares worth $24.5M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 84% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Celgene Corp, an estimated $48M trimmed.
- Perceptive Advisors's largest Q1 2014 buy was Heron Therapeutics: 1,762,426 shares worth $24.5M.
- Perceptive Advisors added most to Clovis Oncology, Inc. in Q1 2014, an estimated $10.4M increase.
- Perceptive Advisors's biggest Q1 2014 reduction was Celgene Corp, cutting an estimated $48M.
- Perceptive Advisors fully exited Aegerion Pharmaceuticals in Q1 2014, selling an estimated $31.8M.
- Perceptive Advisors's ten largest holdings make up 45% of its $952M portfolio in Q1 2014.
- Perceptive Advisors opened 60 new positions and closed 41 in Q1 2014.
- Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $952M.
Based on Perceptive Advisors's 13F filing for Q1 2014, filed 15 May 2014.